Making the Case for Earlier LEMS Screening to Payers

In "Making the Case for Earlier LEMS Screening to Payers," the panel closes the series with a hypothetical pitch to the managed care community.

Dr. Patel poses a hypothetical to close the conversation: if Dr. Iams had the floor at a summit of managed care organizations, PBMs, GPOs, and payers, what case would he make for earlier LEMS screening and diagnosis? Dr. Iams starts with prognosis, explaining that patients with LEMS and small cell lung cancer (SCLC) tend to survive notably longer than the average SCLC patient, in many cases for years, while overall SCLC prognosis remains limited to roughly a year or a year and a half despite incremental treatment advances. That longer survival window, he argues, makes investing in these patients' function and quality of life especially worthwhile. His second point draws on randomized data with amifampridine, where drug withdrawal clearly worsened patient functionality and quality of life, demonstrating that untreated LEMS carries a real functional cost and that amifampridine improves it. He adds a third point about scale: this is a rare cohort, not a request to treat a huge population, yet even within SCLC it represents patients who do meaningfully better and whose remaining time can be improved by this therapy. Dr. Patel calls it an excellent point and offers a closing analogy of his own, describing LEMS as a diagnostic zebra, a term for rare conditions that clinicians rarely encounter directly. He notes that within the specific context of SCLC, that zebra becomes far more likely to appear if a clinician actually looks for it. Dr. Iams agrees and adds his own reference to the classic axiom that clinicians cannot find a fever without checking a temperature, arguing that clinicians similarly cannot find LEMS without ordering VGCC testing, and that having an effective treatment available makes that vigilance worth the effort.

Thank you for watching this AJMC Fireside Chat series on Lambert-Eaton myasthenic syndrome (LEMS) in small cell lung cancer. Please subscribe to our eNewsletter for information on upcoming video series.